Press Releases - Genentech
WEBDec 6, 2010 · Genentech Announces Positive Phase III Results for Inavolisib Combination in People With Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer …
Genentech
WEBExplore how we are applying computation & data science to deliver breakthrough medicines to patients. We're committed to developing an inclusive culture where diversity of thought, style, culture, skill sets and perspective is valued and celebrated.
Genentech: Press Releases | Friday, Oct 15, 2021
WEBOct 15, 2021 · Genentech has been developing medicines to redefine treatment in oncology for more than 35 years, and today, realizing the full potential of cancer immunotherapy is a major area of focus.
Genentech: Media
WEBSep 12, 2024 · Genentech media resources and info for stories in development. Find recent and archived press releases.
News Features - Genentech
WEB64 results. FDA Approves the First and Only Twice-A-Year 10-Minute Subcutaneous Injection for People with Relapsing and Progressive Multiple Sclerosis. On September …
Genentech: Press Releases | Wednesday, Jul 12, 2023
WEBJul 12, 2023 · Positive Phase III Results for Genentech’s Ocrevus (ocrelizumab) Twice a Year, 10-Minute Subcutaneous Injection in Patients With Multiple Sclerosis. Phase III OCARINA II trial met primary and secondary endpoints. Ocrevus 10-minute injection has the potential to further improve the treatment experience and expand Ocrevus® usage in …
Genentech: Press Releases | Tuesday, Nov 21, 2023
WEBNov 21, 2023 · Genentech scientists aim to glean new insights for target and drug discovery and to answer fundamental questions about human biology and disease. The collaboration will also help accelerate Genentech’s “lab in a loop”, where extensive experimental data feeds computational models that uncover patterns and make new, experimentally testable ...
Genentech: Press Releases | Thursday, Apr 18, 2024
WEBApr 18, 2024 · The study included 257 patients who were randomly assigned to either the Alecensa or chemotherapy treatment arm. The primary endpoint is disease-free survival (DFS). Secondary outcome measures include overall survival (OS), central nervous system-DFS, and percentage of patients with adverse events. About lung cancer.
Genentech: Press Releases | Monday, Jul 8, 2024
WEBJul 8, 2024 · About Genentech in Ophthalmology Genentech is researching and developing new treatments for people living with a range of eye diseases that cause significant visual impairment and blindness, including wet age-related macular degeneration (AMD), diabetic macular edema (DME), diabetic retinopathy (DR), …
Genentech: Press Releases | Thursday, Dec 22, 2022
WEBDec 22, 2022 · For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood.